Z-1018

BIOLOGICAL2 trials

Sponsors

Dynavax Technologies Corporation

Conditions

Herpes ZosterShinglesVaccine-Preventable Diseases

Phase 1

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

CompletedNCT05245838

Dynavax Technologies CorporationHerpes Zoster, Shingles, Vaccine-Preventable Diseases

Start: 2022-01-10End: 2022-10-20Updated: 2022-11-07

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Active, not recruitingNCT06569823

Dynavax Technologies CorporationHerpes Zoster, Shingles, Vaccine-Preventable Diseases

Start: 2024-06-17End: 2031-11-01Target: 764Updated: 2026-05-29